Bellevue Asset Management (Switzerland)’s Vertex Pharmaceuticals VRTX Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$8.43M	Sell	67,000 -15,500	-19%	-$1.87M	1.28%	27
2015 Q3	$8.59M	Sell	82,500 -6,000	-7%	-$771K	1.4%	18
2015 Q2	$10.9M	Sell	88,500 -5,000	-5%	-$630K	1.52%	17
2015 Q1	$11M	Buy	+93,500	New	+$11.2M	1.54%	17

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s VRTX Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) reduced its Vertex Pharmaceuticals (VRTX) stake by 19% in Q4 2015, selling an estimated $1.87M and leaving 67,000 shares worth $8.43M. The position accounts for 1.28% of the portfolio, ranked #27.

Bellevue Asset Management (Switzerland) first reported a position in VRTX in Q1 2015 and has held it in 4 quarters since. The position peaked at $11M in Q1 2015. 518 funds tracked by Wall St. Rank hold VRTX as of Q4 2015.

Bellevue Asset Management (Switzerland) held 67,000 shares of Vertex Pharmaceuticals worth $8.43M as of Q4 2015.
Bellevue Asset Management (Switzerland) sold 15,500 Vertex Pharmaceuticals shares in Q4 2015, an estimated $1.87M.
Vertex Pharmaceuticals made up 1.28% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #27 holding.
Bellevue Asset Management (Switzerland) first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 4 quarters since.
Bellevue Asset Management (Switzerland)'s Vertex Pharmaceuticals position peaked at $11M in Q1 2015.
518 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.